CLX Europe Launches New Creative Content Studio in Paris Focused on 3D Scanning Technology
Through CLX Europe's partnership with ALLSIDES Media (previously Covision Media), this cutting-edge studio leverages generative AI, high-resolution 3D scanning, and creative expertise to seamlessly create digital content production for luxury fashion brands and eCommerce players.
"The investment in the new Paris studio reflects our commitment to this iconic market and its most prestigious brands," said Scott Houchin, CEO of CLX Europe. "We are excited to introduce this revolutionary service to our luxury fashion and eCommerce brands and help them redefine how they approach content creation."
"We're excited to partner with CLX Europe and bring our AI-powered 3D scanning solutions to the heart of Paris," said Franz Tschimben, CEO of ALLSIDES Media.
Operational since February 2025, the studio deploys ALLSIDES technology to create immersive, photorealistic content that enhances digital storytelling and engagement. With this digital-first approach to creative content production, the Paris studio will be able to offer:
Automated 3D asset production: Re-lightable, reality-grade models with minimal manual intervention
Scalability and speed: High-volume, customized content creation for fast-paced digital demands
Omnichannel integration: Assets optimized for eCommerce, social media, AR/VR, and virtual try-ons
This approach will also further CLX Europe's mission for more sustainable practices, dramatically reducing waste and greenhouse gas emissions for clients without sacrificing quality.
"This new studio in Paris is a milestone in our journey to blend creativity and sustainability," said Luca Ripamonti, Managing Director, CLX France and Suisse. "Our goal has always been to craft unique, unforgettable content experiences, and with this photorealistic 3D scanning technology, we will be able to break new ground in visual content creation."
With over 50 years of expertise in media production and management, CLX Europe blends precision and creativity to deliver immersive digital experiences for luxury brands. The addition of the Paris studio will not only allow CLX Europe to offer realistic-grade content production for luxury brands, but also open the door for the creation of groundbreaking 3D assets.
About CLX Europe
CLX Europe, an eClerx company, supports global brands, retailers, and agencies in creating, managing, and delivering digital content across multiple channels. With over 50 years of expertise, CLX Europe specializes in leveraging cutting-edge technology to meet the evolving needs of luxury, retail, automotive, and industrial sectors. For more information, visit www.clxeurope.com.
About ALLSIDES Media
ALLSIDES Media is an Italian technology leader in 3D scanning, specializing in mass production of reality-grade, relightable digital twins. Trusted by Inditex Group, NUREG and Adidas, Quad, Meta and other brands, retailers and tech companies, ALLSIDES Media's innovative solutions are reshaping the future of digital content creation. For more information, visit www.covisionmedia.ai.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250618641984/en/
Contacts
Media contact Stefano AnselmiHead of Digital ContentStefano.Anselmi@eclerx.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, Bloomberg News reported that AstraZeneca (NASDAQ:AZN) is in discussions with Summit Therapeutics for a licensing agreement concerning an experimental lung cancer drug, with a potential value of up to $15 billion. The proposed deal for the drug, which is known as ivonescimab, could involve an upfront payment of several billion dollars to Summit, in addition to future milestone payments. However, the talks are ongoing and could still fall apart. Summit might even choose to partner with a different company. Neither Summit nor AstraZeneca has officially commented on the report. A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample. Summit Therapeutics secured the rights to ivonescimab through a separate deal worth up to $5 billion with China-based Akeso in December 2022. Under that agreement, Summit gained exclusive rights to develop and commercialize ivonescimab in the US, Canada, Europe, and Japan, while Akeso (OTC:AKESF) retained rights for other regions, including China. The deal included an upfront payment of $500 million to Akeso and potential regulatory and commercial milestones of up to $4.5 billion. Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that discovers, develops, and commercializes patient, physician, caregiver, and societal-friendly medicinal therapies. AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
Alvotech (ALVO) Announces a Commercialization Agreement With Advanz Pharma
Alvotech (NASDAQ:ALVO) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 1, Alvotech (NASDAQ:ALVO) and Advanz Pharma announced a commercialization agreement to distribute and supply AVT10, a biosimilar candidate to Cimzia, in Europe. A scientist in a laboratory working on drug research. The agreement is expected to support Alvotech's (NASDAQ:ALVO) strategic position in the biosimilar market while allowing increased access to high-quality biologics in Europe. This could potentially affect the market share of the current treatments in the chronic rheumatic diseases sector. Alvotech (NASDAQ:ALVO) is a biotechnology company that develops and manufactures biosimilar medicines. Headquartered in Luxembourg, the company operates in the following geographical segments: Europe, North America, Asia, and Other. While we acknowledge the potential of ALVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
an hour ago
- Yahoo
HubSpot Expands CRM Expertise Through Partnership with MatrixPoint
HubSpot Inc. (NYSE:HUBS) is one of the best NYSE stocks to buy for long term investment. As May was coming to an end, MatrixPoint announced its collaboration with HubSpot by joining its Solutions Partner Program. The partnership will enhance customer engagement and expand CRM/Customer Relationship Management expertise. The HubSpot Solutions Partner Program is a global network of experts providing services in marketing, sales, customer service, web design, CRM, and IT. This ecosystem emphasizes a customer-first approach for growth, which enables its members, like MatrixPoint, to offer a wider range of sophisticated solutions. A team of software developers gathered around a monitor discussing a new CRM platform. MatrixPoint is a results-driven media consultancy that empowers businesses to achieve more through marketing transformation and strategic growth. It will specifically expand its CRM practice through this partnership to help clients better use their customer data for more intelligent and personalized engagement. HubSpot Inc. (NYSE:HUBS) provides a cloud-based CRM platform for businesses in the Americas, Europe, and the Asia Pacific. While we acknowledge the potential of HUBS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
